The following discloses the conflicts of interest of the members of the Joint Working Group of the Japan Pediatric Society and the Japan Atherosclerosis Society for the Development of Guidelines for the Treatment of Pediatric Familial Hypercholesterolemia for the years 2017 - 2021.
| Names | Disclosure Item 1 | Disclosure Item 2 | Disclosure Item 3 | Disclosure Item 4 | Disclosure Item 5 | Disclosure Item 6 |
| Disclosure Item 7 | Disclosure Item 8 | Disclosure Item 9 | Disclosure Item 10 | Disclosure Item 11 | Disclosure Item 12 | |
| Ohtake A. | None | None | None | Sanofi K.K. | None |
SBI Pharmaceuticals Co., Ltd. |
| None | None | None | None | None | None | |
| Okada H. | None | None | None | None | None | None |
| None | None | None | None | None | None | |
| Ogura M. | None | None | None |
Astellas Pharma Inc., Amgen Astellas BioPharma K.K., Sanofi K.K., Kowa Company, Ltd., Amgen K.K. |
None | None |
| None | None | None | None | None | None | |
| Kataoka Y. | None | None | None | None | None | None |
| None | None | None | None | None | None | |
| Harada- Shiba M. | None | Liid Pharmaceuticals, Inc. | None | Astellas Pharma Inc., Amgen K.K., Amgen Astellas BioPharma K.K., Kaneka Medix Corporation, Sanofi K.K. | None | Aegerion Pharmaceuticals, Inc. , Parexel International Inc. |
| Aegerion Pharmaceuticals, Inc. , MSD K.K., Kaneka Medix Corporation, Kowa Pharmaceutical Co. Ltd., Sanofi K.K., Takeda Pharmaceutical Company Limited, Recordati Rare Diseases | None | None | None | None | None | |
| Sugiyama D. | Ajinomoto Frozen Foods Co., Inc. | None | None | None | None | None |
| None | None | None | None | None | None | |
| Tada H. | None | None | None | None | None | None |
| None | None | None | None | None | None | |
| Tanaka Y. | None | None | None | None | None | None |
| American Heart Association (AHA), JAPAN LIFELINE Co., Ltd. | None | None | None | None | None | |
| Doi T. | None | None | None | None | None | None |
| None | None | None | None | None | None | |
| Dobashi K. | None | None | None | None | None | None |
| None | None | None | None | None | None | |
| Nishikawa T. | None | None | None | None | None | None |
| None | None | None | None | None | None | |
| Nomura A. | CureApp, Inc. | None | None | None | None | None |
| None | None | None | None | None | None | |
| Matsuki K. | None | None | None | None | None | None |
| None | None | None | None | None | None | |
| Minamino T. | None | None | None | Daiichi Sankyo Company, Limited, Nippon Boehringer Ingelheim Co., Ltd. | None | A&D Company, Limited, OMRON Corporation, Matsutani Chemical Industry Co.,Ltd., Melody International Ltd. |
| Astellas Pharma Inc., Otsuka Pharmaceutical Co., Ltd.,Kyowa Hakko Kirin Co., Ltd., Kyowa Kirin Co., Ltd., Sanofi K.K.,Takeda Pharmaceutical Company Limited, MitsubishiTanabe Pharma Corporation | None | None | None | None | None | |
| Yamashita S. | None | None | None | Amgen K.K., MSD K.K., Otsuka Pharmaceutical Co., Ltd., Kowa Company, Ltd., Skylight Biotech,Inc., Novartis Pharma K.K., Bayer Yakuhin,Ltd,, Hayashibara Co., Ltd., East Japan Institute ofTechnology Co., Ltd. | None | Medical Photonics Co.,Ltd. |
|
ONO PHARMACEUTICAL CO., LTD., Nippon Boehringer Ingelheim Co., Ltd., MSD K.K. |
None | None | None | None | None | |
| Yamamoto Y. | None | None | None | None | None | None |
| None | None | None | None | None | None | |
| Yamamoto M. | None | None | None | None | None | None |
| None | None | None | None | None | None |
【Disclosure Item】
1.Assuming a position of a board member or advisor in a profit-making business,/ Advisory role (1,000,000 yen or more annual compensation from a single business entity, or group)
2.Stock holdings or options (Annual profit of 1,000,000 yen or more/ownership of 5% or more of total shares)
3.Patent royalties/licensing fees (1,000,000 yen or more annual income per patent)
4.Honoraria (e.g. lecture fees) (500,000 yen or more total annual income from a single company or organization)
5.Fees for promotional materials (e.g. manuscript fee) (500,000 yen or more total annual income from a single company or organization)
6.Total clinical research funding (1,000,000 yen or more total annual research grants paid from a single company or organization to you or your department)
7.Total scholarship grants (1,000,000 yen or more total annual scholarship contributed by a single company or organization to you or your department)
8.Courses endowed by companies (Fill in if you belong to any course endowed by a company, etc.)
9.Others (e.g. trips, travel, or gifts, which are not related to research) (50,000 yen or more annually from a single company or organization)
Matters declared by the author's spouse, relatives within the first degree of consanguinity, or persons who share income or property
10.Assuming a position of a board member or advisor in a profit-making business,/ Advisory role (1,000,000 yen or more annual compensation from a single business entity, or group)
11.Stock holdings or options (Annual profit of 1,000,000 yen or more/ownership of 5% or more of total shares)
12.Patent royalties/licensing fees (1,000,000 yen or more annual income per patent)
＊The company name is the name of the company as it was at the time of filing.